STOCK TITAN
  1. Home
  2. Sec-filings
  3. ONC
  4. [Form 4] BeOne Medicines Ltd. Insider Trading Activity

BeOne Medicines (ONC) CEO exercises options and sells 109,713 ADSs

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

BeOne Medicines Ltd. director and Chief Executive Officer John Oyler exercised share options covering 441,870 Ordinary Shares at an exercise price of $9.23 per share and on the same date acquired 33,990 American Depositary Shares through an exercise or conversion transaction at $119.96 per ADS.

On July 20–21, 2026, he sold an aggregate 109,713 American Depositary Shares in multiple open-market or private transactions at weighted-average prices within ranges from $309.39 to $320.39 per ADS under a Rule 10b5-1 trading plan adopted on March 10, 2026. After these trades he reported 4,461,518 Ordinary Shares held directly, plus additional Ordinary Shares held indirectly through various trusts and entities, some of which he disclaims beneficial ownership. Each American Depositary Share represents 13 Ordinary Shares.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider OYLER JOHN
Role Chief Executive Officer
Sold 109,713 shs ($34.59M)
Approx. gross sale proceeds $34.59M
Approx. exercise cost $4.08M
Type Security Shares Price Value
Sale American Depositary Shares F6, F7, F16 15,379 $316.2602 $4.86M
Sale American Depositary Shares F6, F7, F17 20,029 $316.9075 $6.35M
Sale American Depositary Shares F6, F7, F18 7,842 $318.4133 $2.50M
Sale American Depositary Shares F6, F7, F19 15,807 $319.2901 $5.05M
Sale American Depositary Shares F6, F7, F20 2,340 $320.0583 $749K
Exercise Share Option (Right to Buy) F21, F22 441,870 $0.00 $0.00
Sale American Depositary Shares F6, F7, F8 5,146 $310.0812 $1.60M
Sale American Depositary Shares F6, F7, F9 6,273 $310.7461 $1.95M
Sale American Depositary Shares F6, F7, F10 2,907 $311.7952 $906K
Exercise American Depositary Shares F6 33,990 $119.96 $4.08M
Sale American Depositary Shares F6, F7, F11 15,499 $312.2856 $4.84M
Sale American Depositary Shares F6, F7, F12 14,326 $312.9578 $4.48M
Sale American Depositary Shares F6, F7, F13 1,850 $313.909 $581K
Sale American Depositary Shares F6, F7, F14 1,512 $315.263 $477K
Sale American Depositary Shares F6, F7, F15 523 $316.1363 $165K
Sale American Depositary Shares F6, F7 280 $318.30 $89K
holding Ordinary Shares -- -- --
holding Ordinary Shares F1 -- -- --
holding Ordinary Shares F2 -- -- --
holding Ordinary Shares F3 -- -- --
holding Ordinary Shares F4 -- -- --
holding Ordinary Shares F5 -- -- --
Holdings After Transaction: Share Option (Right to Buy) — 0 shares (Direct); American Depositary Shares — 0 shares (Direct); Ordinary Shares — 4,461,518 shares (Direct); Ordinary Shares — 46,031,994 shares (Indirect, See Footnote)
Footnotes (22)
  1. F1. These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership.
  2. F2. These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
  3. F3. These securities are held by Oyler Investment LLC, of which 99% of the limited liability company interests are owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
  4. F4. These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account.
  5. F5. These securities are held by The John Oyler Legacy Trust for the benefit of the Reporting Person's child, for which the Reporting Person disclaims beneficial ownership.
  6. F6. Each American Depositary Share represents 13 Ordinary Shares.
  7. F7. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026.
  8. F8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $309.39 to $310.38, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
  9. F9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $310.39 to $311.36, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
  10. F10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $311.46 to $311.98, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
  11. F11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $311.98 to $312.45, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
  12. F12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $312.46 to $313.39, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
  13. F13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $313.47 to $314.36, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
  14. F14. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $314.74 to $315.60, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
  15. F15. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $315.91 to $316.33, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
  16. F16. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $315.67 to $316.66, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
  17. F17. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $316.67 to $317.62, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
  18. F18. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $317.72 to $318.685, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
  19. F19. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $318.79 to $319.78, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
  20. F20. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $319.82 to $320.39, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
  21. F21. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.
  22. F22. These securities vest over a four-year period as follows: 25% on June 5, 2020, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events.
ADS sold 109,713 American Depositary Shares Aggregate ADS sales by John Oyler on July 20–21, 2026
Option exercise shares 441,870 Ordinary Shares Shares underlying options exercised on July 20, 2026
Option exercise price $9.23 per Ordinary Share Exercise price of share options expiring June 4, 2029
ADS acquired via exercise/conversion 33,990 American Depositary Shares Non-derivative transaction coded as exercise/conversion at $119.96 per ADS
Direct Ordinary Share holdings 4,461,518 Ordinary Shares Direct holdings reported as of July 20, 2026
ADS sale price ranges $309.39 to $320.39 per ADS Weighted-average price ranges for multiple ADS sales on July 20–21, 2026
ADS-to-Ordinary ratio 1 ADS = 13 Ordinary Shares Representation for BeOne Medicines American Depositary Shares
Rule 10b5-1 trading plan regulatory
"The sale was effected pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
American Depositary Shares financial
"Each American Depositary Share represents 13 Ordinary Shares."
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
grantor retained annuity trust financial
"These securities are held in a grantor retained annuity trust"
A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Roth IRA PENSCO trust account financial
"held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider stock sales did BeOne Medicines (ONC) CEO John Oyler report?
John Oyler reported selling an aggregate 109,713 American Depositary Shares on July 20–21, 2026 at weighted-average prices within ranges from $309.39 to $320.39 per ADS in multiple open-market or private transactions under a Rule 10b5-1 trading plan.

What stock options did BeOne Medicines (ONC) CEO John Oyler exercise?
He exercised share options covering 441,870 Ordinary Shares at an exercise price of $9.23 per Ordinary Share, with the option position reduced to zero and an expiration date of June 4, 2029 noted for the exercised award.

Were the BeOne Medicines (ONC) insider sales made under a Rule 10b5-1 plan?
Yes. Footnotes state each sale was effected under a Rule 10b5-1 trading plan adopted by John Oyler on March 10, 2026, and the filing’s Rule 10b5-1 checkbox is affirmatively marked, indicating the transactions were pre-arranged under that plan.

What are John Oyler’s reported direct share holdings in BeOne Medicines (ONC)?
After the reported transactions, John Oyler listed 4,461,518 Ordinary Shares held directly. Additional Ordinary Shares are held indirectly through various trusts and entities, and for several of those indirect holdings he disclaims beneficial ownership in the footnotes.

How do BeOne Medicines (ONC) American Depositary Shares relate to Ordinary Shares?
Each BeOne Medicines American Depositary Share represents 13 Ordinary Shares, according to the footnotes. The reported insider trades therefore involve ADSs that correspond to underlying Ordinary Shares in this fixed 13-to-1 ratio.

Did BeOne Medicines (ONC) CEO acquire any ADSs in addition to selling them?
Yes. On July 20, 2026, John Oyler reported acquiring 33,990 American Depositary Shares in a transaction coded as an exercise or conversion at a transaction price of $119.96 per ADS, separate from his subsequent open-market or private sales.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
OYLER JOHN
(Last)(First)(Middle)
C/O BEONE MEDICINES I GMBH
AESCHENGRABEN 27, 21ST FLOOR
(Street)
BASEL4051
(City)(State)(Zip)
SWITZERLAND
(Country)		2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/20/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares4,461,518D
Ordinary Shares481,533ISee Footnote(1)
Ordinary Shares7,699,158ISee Footnote(2)
Ordinary Shares28,204,115ISee Footnote(3)
Ordinary Shares9,545,000ISee Footnote(4)
Ordinary Shares102,188ISee Footnote(5)
American Depositary Shares(6)07/20/2026S(7)5,146D$310.0812(8)9,180D
American Depositary Shares(6)07/20/2026S(7)6,273D$310.7461(9)2,907D
American Depositary Shares(6)07/20/2026S(7)2,907D$311.7952(10)0D
American Depositary Shares(6)07/20/2026M33,990A$119.9633,990D
American Depositary Shares(6)07/20/2026S(7)15,499D$312.2856(11)18,491D
American Depositary Shares(6)07/20/2026S(7)14,326D$312.9578(12)4,165D
American Depositary Shares(6)07/20/2026S(7)1,850D$313.909(13)2,315D
American Depositary Shares(6)07/20/2026S(7)1,512D$315.263(14)803D
American Depositary Shares(6)07/20/2026S(7)523D$316.1363(15)280D
American Depositary Shares(6)07/20/2026S(7)280D$318.30D
American Depositary Shares(6)07/21/2026S(7)15,379D$316.2602(16)46,018D
American Depositary Shares(6)07/21/2026S(7)20,029D$316.9075(17)25,989D
American Depositary Shares(6)07/21/2026S(7)7,842D$318.4133(18)18,147D
American Depositary Shares(6)07/21/2026S(7)15,807D$319.2901(19)2,340D
American Depositary Shares(6)07/21/2026S(7)2,340D$320.0583(20)0D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option (Right to Buy)$9.23(21)07/20/2026M441,870 (22)06/04/2029Ordinary Shares441,870$00D
Explanation of Responses:
1. These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership.
2. These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
3. These securities are held by Oyler Investment LLC, of which 99% of the limited liability company interests are owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
4. These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account.
5. These securities are held by The John Oyler Legacy Trust for the benefit of the Reporting Person's child, for which the Reporting Person disclaims beneficial ownership.
6. Each American Depositary Share represents 13 Ordinary Shares.
7. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026.
8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $309.39 to $310.38, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $310.39 to $311.36, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $311.46 to $311.98, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $311.98 to $312.45, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $312.46 to $313.39, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $313.47 to $314.36, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
14. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $314.74 to $315.60, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
15. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $315.91 to $316.33, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
16. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $315.67 to $316.66, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
17. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $316.67 to $317.62, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
18. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $317.72 to $318.685, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
19. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $318.79 to $319.78, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
20. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $319.82 to $320.39, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
21. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.
22. These securities vest over a four-year period as follows: 25% on June 5, 2020, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events.
Remarks:
/s/ Frank Collazo, as Attorney-in-Fact07/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR